Key result
Rebamipide is a promising cytoprotective agent for preventing and treating NSAID-induced small bowel injuries, offering pleiotropic effects without significant cytochrome P-450 drug interactions.
Why the study?
Does rebamipide prevent and treat small bowel injuries in patients receiving NSAIDs or antiplatelet therapy?
Does rebamipide prevent and treat small bowel injuries in patients receiving NSAIDs or antiplatelet therapy?
Answers are grounded in this paper and cite their sources.
Rebamipide represents a promising therapeutic option for preventing and treating small bowel enteropathy induced by NSAIDs and antiplatelet therapy, particularly given its lack of cytochrome P450 interactions.
Nonsteroidal anti-inflammatory drug (NSAID)-induced small bowel injuries (NSAID enteropathies) become clinically important. Videocapsule endoscopy shows that the small bowel is involved in NSAID-related gastrointestinal tract (GIT) injury in almost two-thirds of all cases. Due to a large number of patients who receive NSAIDs, combined antiplatelet therapy, or long use anticoagulants, GIT injury prevention becomes an actual problem. Treatment for NSAID enteropathy is different from that for NSAID gastropathy. In NSAID enteropathy, it is advisable to use drugs that are able to increase the production of prostaglandins and mucus, to restore intestinal epithelial permeability, and to exert anti-inflammatory and antioxidant effects. Rebamipide that produces many pleiotropic effects and also has cytoprotective properties may become the drug of choice for treating patients with NSAID enteropathy. In addition, rebamipide has no effects on various cytochrome P-450 enzyme systems, by reducing the risk of drug interactions.
No takes yet. Share an insight, caveat, or question.
Драпкина et al. (2016) conducted a review in NSAID-induced small bowel injury (NSAID enteropathy). Rebamipide was evaluated. Rebamipide is a promising cytoprotective agent for preventing and treating NSAID-induced small bowel injuries, offering pleiotropic effects without significant cytochrome P-450 drug interactions.
Synapse has enriched 10 related papers. Consider them for comparative context: